NCTx

What NCTx does

NCTx is a consumer-facing metabolic health brand operated by eXoZymes Inc. (Nasdaq: EXOZ), a synthetic biology company headquartered in Monrovia, California. The company commercializes Nicotinoyl Glycine (NCT), a molecule that was historically structurally unavailable for commercial use due to production constraints, by leveraging an AI-enhanced enzyme platform ("exozymes") and a cell-free production architecture. The exozyme cascade converts simple feedstocks directly into NCT with engineering-level control, yielding a single molecular species at pharma-grade purity with high conversion efficiency — a process the company states moved from concept to gram-scale production within months. The platform extends beyond NCT into additional biosolution pipelines for cannabinoids and santalene, and a separate pharmaceutical track (NCT: Pharma).

Name

NCTx

Legal name

eXoZymes Inc.

Website

https://nctx.one

Company type

Public

Founded year

2019

Operating status

Operating

Short description

eXoZymes Inc. (Nasdaq: EXOZ) operates the NCTx metabolic health brand, commercializing Nicotinoyl Glycine via an AI-enhanced exozyme cascade and cell-free production platform. It serves consumers through DTC products and wellness brands via ingredient supply and white-label partnerships.

Ownership category

akta.pro rank

Product category

Metabolic Health Ingredients & Supplements

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Metabolic health supplements
• Cell-free bioproduction
• Exozyme cascade technology
• Wellness ingredient supply
• Pharma-grade manufacturing

Headquarters

HQ city

Monrovia

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Direct-to-Consumer Branded Products: Branded NCT metabolic health products sold directly to consumers, focusing on cellular performance rather than symptomatic relief.
2. Ingredient Supply: Supply of NCT as an ingredient to established wellness brands for incorporation into their products.
3. White-Label Partnerships: Selective white-label partnerships allowing other brands to use NCT in their own branded products.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Core offering

eXoZymes Inc. (commercial brand NCTx) develops and commercializes metabolic health products based on Nicotinoyl Glycine (NCT), a molecule previously structurally unavailable at scale. The company manufactures NCT using a proprietary cell-free production platform driven by AI-enhanced exozymes arranged in an exozyme cascade, yielding a single molecular species with pharma-grade purity. Commercialization combines direct-to-consumer branded products (Pure NCT over-the-counter) with ingredient supply to wellness brands and selective white-label partnerships.

Product overview

eXoZymes offers Pure NCT as a foundational metabolic health product. The company operates a platform-based business model combining direct-to-consumer branded products with ingredient supply to established wellness brands and white-label partnerships. The NCT portfolio includes both over-the-counter wellness products (Pure NCT) and a pharmaceutical track (NCT: Pharma), alongside other biosolution pipelines for cannabinoids and santalene. The platform leverages AI-enhanced enzymes (exozymes) and cell-free production technology to manufacture NCT with engineering-level control, achieving consistent pharma-grade purity.

Differentiator

Problem solved

Functional benefit

Products and services

• Pure NCT (Over-the-Counter) A metabolic health supplement product based on Nicotinoyl Glycine (NCT), designed to support cellular performance rather than symptomatic relief. Manufactured using eXoZymes' AI-enhanced exozymes and cell-free production platform, yielding pharma-grade purity with a single molecular species. Sold as a branded over-the-counter product to health-conscious consumers and offered through direct-to-consumer e-commerce.

Quantifiable outcome

• NCT moved from concept to gram-scale production within months

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Zymergen: Synthetic biology and automation company (now part of Ginkgo Bioworks) developing bio-based products for materials and pharmaceuticals. Comparable as a broader synthetic biology incumbent with bioprocessing capabilities relevant to enzymatic production.
• Lonza: Global CDMO with capabilities in mammalian and microbial fermentation, including small molecule API production. Comparable as a large-scale biomanufacturing platform with pharma-grade production capabilities, though serving many customers rather than own products.

Direct peers

• Ginkgo Bioworks: Cell engineering and synthetic biology platform developing organisms to produce industrial molecules. Highly comparable as a programmable biology platform targeting ingredient production, with significantly greater scale and capital base than eXoZymes.
• Elysium Health: Consumer health company selling science-based cellular health supplements including NAD+ boosting products. Comparable as a premium-positioned direct-to-consumer supplement company focused on cellular performance and longevity.
• ChromaDex: Science-based wellness company selling NAD+ precursor supplements (NMN, NR) for cellular health and longevity. Directly comparable in the metabolic health / cellular performance consumer supplement category that NCTx is entering with NCT.
• Codexis: Engineered enzyme platform company developing biocatalysts for pharmaceutical and sustainable chemical manufacturing. Closely comparable as an enzyme engineering company with a platform technology serving pharmaceutical production.
• Amyris: Synthetic biology company that engineered yeast to produce specialty ingredients including cannabinoids and squalane. Comparable business model combining cell-based production with branded consumer products and ingredient supply to established brands.
• Demetrix: Biotech company using fermentation to produce rare cannabinoids at commercial scale. Directly comparable as a synthetic biology platform producing a specific molecule (cannabinoids) that was previously structurally unavailable—parallel positioning to NCTx's NCT molecule.
• Conagen: Synthetic biology company producing high-value ingredients through fermentation for food, cosmetic, and pharmaceutical applications. Comparable as a biotech platform producing novel molecules for commercial ingredient supply.

Emerging players

• Bota Bio: Synthetic biology platform developing sustainable ingredients and bio-based products using engineered microorganisms. Comparable as an emerging programmable biology platform with multi-product ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NCTx